We use cookies to improve your experience on this website. Read More Allow Cookies

Pfizer quarterly profits beat market estimates

31 October, 2017

Pfizer’s quarterly profit beat market estimates, in part helped by higher-than-expected sales of its blockbuster pneumonia vaccine Prevnar.

Pfizer sold $1.52 billion worth of Prevnar in the third quarter, down nearly 1 per cent from a year earlier, but ahead of analysts’ estimate of $1.46 billion. 

For more on this story: